This makes the AAV‐BR1 a highly promising vector for the treatment of NPC2 disease and other LSD with CNS involvement caused by a lack of secretory protein, for example, Krabbe disease, Gaucher disease, and Mucopolysaccharidoses (Edelmann & Maegawa, 2020). This evidence concerns the gene CXCL11 and mucopolysaccharidosis.